

Waldenstrom Macroglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/WD43BD912C88EN.html>

Date: May 2024

Pages: 140

Price: US\$ 6,499.00 (Single User License)

ID: WD43BD912C88EN

Abstracts

The 7 major Waldenstrom macroglobulinemia markets reached a value of US\$ 152.1 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 234.2 Million by 2034, exhibiting a growth rate (CAGR) of 4% during 2024-2034.

The Waldenstrom macroglobulinemia market has been comprehensively analyzed in IMARC's new report titled "Waldenstrom Macroglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034".

Waldenstrom macroglobulinemia refers to a rare form of cancer that belongs to a group of disorders known as lymphoproliferative neoplasms. It is characterized by the overproduction of a specific type of abnormal white blood cell called lymphoplasmacytic cells, which accumulate in the bone marrow and produce monoclonal immunoglobulin M (IgM) protein. The most common symptoms associated with the illness include fatigue, weakness, enlarged lymph nodes and spleen, anemia, bleeding problems, easy bruising, nosebleeds, etc. Individuals suffering from this ailment may also experience indications related to high levels of IgM, such as thickened blood or hyperviscosity. The diagnosis of Waldenstrom macroglobulinemia involves several steps, including medical history evaluation, physical examination, laboratory tests, and imaging studies. A bone marrow biopsy is also crucial to detect characteristic findings and confirm the presence of abnormal lymphocytes in patients. The healthcare provider may further perform numerous other diagnostic procedures and tests, like a complete blood count, a computed tomography scan, serum protein electrophoresis, etc., to validate the underlying cause as well as evaluate the extent and spread of the disease.

The increasing cases of inherited disorders resulting from genetic mutations, which cause uncontrolled growth and accumulation of lymphoplasmacytic cells, are primarily

driving the Waldenstrom macroglobulinemia market. In addition to this, the growing geriatric population, who are susceptible to various physiological changes and impaired immune system functioning, is creating a positive outlook for the market. Moreover, the widespread adoption of chemotherapy regimens, including bendamustine, cyclophosphamide, fludarabine, etc., to alleviate disease symptoms by reducing the proliferation of cancerous cells and decreasing the production of abnormal proteins is further bolstering the market growth. Apart from this, the escalating application of plasmapheresis procedures, since they help to lower the concentration of IgM, thereby enhancing blood flow and preventing complications related to high serum viscosity, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of interferon-alpha therapy to treat the disorder owing to its several associated benefits, such as stimulating the immune system, inhibiting cell growth, and improving disease control, is expected to drive the Waldenstrom macroglobulinemia market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Waldenstrom macroglobulinemia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Waldenstrom macroglobulinemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Waldenstrom macroglobulinemia market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Waldenstrom macroglobulinemia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Waldenstrom macroglobulinemia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Waldenstrom macroglobulinemia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

How has the Waldenstrom macroglobulinemia market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Waldenstrom macroglobulinemia market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Waldenstrom macroglobulinemia market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia across the seven major markets?

What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Waldenstrom macroglobulinemia by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with Waldenstrom macroglobulinemia across the seven major markets?

What is the size of the Waldenstrom macroglobulinemia patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Waldenstrom macroglobulinemia?

What will be the growth rate of patients across the seven major markets?

Waldenstrom Macroglobulinemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Waldenstrom macroglobulinemia drugs

across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Waldenstrom macroglobulinemia market?

What are the key regulatory events related to the Waldenstrom macroglobulinemia market?

What is the structure of clinical trial landscape by status related to the Waldenstrom macroglobulinemia market?

What is the structure of clinical trial landscape by phase related to the Waldenstrom macroglobulinemia market?

What is the structure of clinical trial landscape by route of administration related to the Waldenstrom macroglobulinemia market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 WALDENSTROM MACROGLOBULINEMIA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 WALDENSTROM MACROGLOBULINEMIA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 WALDENSTROM MACROGLOBULINEMIA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 WALDENSTROM MACROGLOBULINEMIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 WALDENSTROM MACROGLOBULINEMIA - UNMET NEEDS

10 WALDENSTROM MACROGLOBULINEMIA - KEY ENDPOINTS OF TREATMENT

11 WALDENSTROM MACROGLOBULINEMIA - MARKETED PRODUCTS

- 11.1 List of Waldenstrom Macroglobulinemia Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Brukinsa (Zanubrutinib) - BeiGene
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Imbruvica (Ibrutinib) - Janssen/Pharmacyclics

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 WALDENSTROM MACROGLOBULINEMIA - PIPELINE DRUGS

12.1 List of Waldenstrom Macroglobulinemia Pipeline Drugs Across the Top 7 Markets

12.1.1 Ulocuplumab - Bristol-Myers Squibb

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

12.1.2 APG2575 - Ascentage Pharma

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

12.1.3 Acalabrutinib - Acerta Pharma/AstraZeneca

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

12.1.4 Pirtobrutinib - Eli Lilly and Company

- 12.1.4.1 Drug Overview
- 12.1.4.2 Mechanism of Action
- 12.1.4.3 Clinical Trial Results
- 12.1.4.4 Safety and Efficacy
- 12.1.4.5 Regulatory Status

12.1.5 Daratumumab - Janssen Biotech

- 12.1.5.1 Drug Overview
- 12.1.5.2 Mechanism of Action
- 12.1.5.3 Clinical Trial Results

12.1.5.4 Safety and Efficacy

12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. WALDENSTROM MACROGLOBULINEMIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. WALDENSTROM MACROGLOBULINEMIA – CLINICAL TRIAL LANDSCAPE

14.1 Drugs by Status

14.2 Drugs by Phase

14.3 Drugs by Route of Administration

14.4 Key Regulatory Events

15 WALDENSTROM MACROGLOBULINEMIA - MARKET SCENARIO

15.1 Market Scenario - Key Insights

15.2 Market Scenario - Top 7 Markets

15.2.1 Waldenstrom Macroglobulinemia - Market Size

15.2.1.1 Market Size (2018-2023)

15.2.1.2 Market Forecast (2024-2034)

15.2.2 Waldenstrom Macroglobulinemia - Market Size by Therapies

15.2.2.1 Market Size by Therapies (2018-2023)

15.2.2.2 Market Forecast by Therapies (2024-2034)

15.3 Market Scenario - United States

15.3.1 Waldenstrom Macroglobulinemia - Market Size

15.3.1.1 Market Size (2018-2023)

15.3.1.2 Market Forecast (2024-2034)

15.3.2 Waldenstrom Macroglobulinemia - Market Size by Therapies

15.3.2.1 Market Size by Therapies (2018-2023)

15.3.2.2 Market Forecast by Therapies (2024-2034)

15.3.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview

15.4 Market Scenario - Germany

15.4.1 Waldenstrom Macroglobulinemia - Market Size

15.4.1.1 Market Size (2018-2023)

15.4.1.2 Market Forecast (2024-2034)

15.4.2 Waldenstrom Macroglobulinemia - Market Size by Therapies

15.4.2.1 Market Size by Therapies (2018-2023)

- 15.4.2.2 Market Forecast by Therapies (2024-2034)
- 15.4.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Waldenstrom Macroglobulinemia - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
 - 15.5.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Waldenstrom Macroglobulinemia - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Waldenstrom Macroglobulinemia - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Waldenstrom Macroglobulinemia - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Waldenstrom Macroglobulinemia - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Waldenstrom Macroglobulinemia - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Waldenstrom Macroglobulinemia - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034)

15.9.3 Waldenstrom Macroglobulinemia - Access and Reimbursement Overview

16 WALDENSTROM MACROGLOBULINEMIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 WALDENSTROM MACROGLOBULINEMIA MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 WALDENSTROM MACROGLOBULINEMIA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Waldenstrom Macroglobulinemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/WD43BD912C88EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/WD43BD912C88EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

